A practical reference on Backbone hydrolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-07. Anything still debated is marked as such rather than presented as settled.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, solid | Approximately -20 C | Sealed, desiccated, protected from light |
| Typical identity method | Electrospray mass spectrometry | Protonated ion expected near 391 |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Common synonyms | Epithalon, epithalone, AEDG | Spelling variants appear in supplier catalogues |
| Solution stability | Days at 2-8 C | Hydrolysis and deamidation limit shelf life |
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
The light source shines onto or through the sample. The sample transmits or reflects light. The detector detects how much light was reflected from or transmitted through the sample. The detector then converts how much light the sample transmitted or reflected into a number.
eV, higher than what is predicted in theory for continuum plates of the same thickness, due to nonlocal microstructural constraints such as nonlocal coupling of particle rotational degrees of freedom. On the other hand, resistance to bending is found to be greatly reduced in nanoparticle monolayers that are supported at the air/water interface, possibly due to screening of ligand interactions in a wet environment.
== Entertainment == Serbia and Montenegro participated in the Eurovision Song Contest on two occasions and in Junior Eurovision Song Contest 2005 only on one occasion. The country debuted in the Eurovision Song Contest under the name Serbia and Montenegro in 2004, when Željko Joksimović got second place. In 2006, the year of Montenegrin independence, the country Serbia and Montenegro did not have a representative due to the scandal in Evropesma 2006, but was still able to vote in both the semi-final and the final.
Intravenous acetylcysteine has the advantage of shortening hospital stay, increasing both doctor and patient convenience, and allowing administration of activated charcoal to reduce absorption of both the paracetamol and any co-ingested drugs without concerns about interference with oral acetylcysteine. Intravenous dosing varies with weight, specifically in children. For patients less than 20 kg, the loading dose is 150 mg/kg in 3 mL/kg diluent, administered over 60 minutes; the second dose is 50 mg/kg in 7 mL/kg diluent over 4 hours; and the third and final dose is 100 mg/kg in 14 mL/kg diluent over 16 hours. Because of the risk of adverse events, electrolyte derangements and fluid shifts associated with larger doses of acetylcysteine dose capping regimens have been suggested. To date no increased risk of hepatic injury or failure has been noted with this dose capping strategy. The most common adverse effect to acetylcysteine treatment is an anaphylactoid reaction, usually manifested by rash, wheeze, or mild hypotension. Adverse reactions are more common in people treated with IV acetylcysteine, occurring in up to 20% of patients. Anaphylactoid reactions are more likely to occur with the first infusion (the loading dose). Rarely, severe life-threatening reactions may occur in predisposed individuals, such as patients with asthma or atopic dermatitis, and may be characterized by respiratory distress, facial swelling, and even death.
=== Serotonin precursors === The serotonin precursors tryptophan and 5-hydroxytryptophan (5-HTP; oxitriptan) are available as over-the-counter supplements. They are often used to produce sleepiness and treat insomnia. However, little to no clinical data exist to support their use or effectiveness.
Sources: en.wikipedia.org
==== Positive ion formation ==== Once the metastable carrier gas atoms (M*) released from the source, they initiate Penning ionization of nitrogen, atmospheric water and other gaseous species. Although some compounds can be ionized directly by Penning ionization, the most common positive-ion formation mechanism for DART involves ionization of atmospheric water.
== Toxicity == An in silico Study analyzing potential risks of 3-HO-PCE, along with other related substances, found multiple potential risks. One such risk was a high probability of hERG blockades, suggesting that QT-prolongation could be present in use. The lungs, liver, and blood were all found to be prominent likely toxicity targets of this class of drugs. The LD50 of 3-HO-PCE and related substances in rats was consistently between 200-630mg/kg orally, indicating moderate oral toxicity.
Prix Galien CEE Pro Bono Humanum Award: In November 2025, Thomsen accepted the Prix Galien CEE Pro Bono Humanum Award on behalf of the Novo Nordisk Foundation, which received the distinction for its contributions to global health initiatives and scientific research. The award was presented at the Central and Eastern Europe edition of the Prix Galien programme in Warsaw, Poland. PwC Business Executive of the Year 2025: In 2025, Thomsen received PwC Denmark's Business Executive of the Year award. The distinction is presented annually to executives in Danish business who have demonstrated notable leadership, strategic influence, and impact on society. PwC's award committee highlighted Thomsen's role in leading the Novo Nordisk Foundation and its expansion of scientific, global health and sustainability initiatives. Golden Plate Award (2024): Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. Knight of the Order of the Dannebrog: On December 12, 2022, he was appointed as a Knight of the Order of the Dannebrog by the Danish Royal House
The monofunctional monomer, often referred to as a chain stopper, controls and limits the polymerization of bifunctional monomers because the growing polymer yields chain ends devoid of functional groups and therefore incapable of further reaction.
It is particularly concerning as those consequences happen while the brain is still developing. The degree to which the sleep is disturbed and fragmented has been significantly linked to the severity of the consequences, the latter having the possibility to decrease once the sleep is improved. It is more the disruption of sleep processes than the total amount of sleep the child experience that generates the adverse consequences on the child's daytime functioning; it contributes to the hyperactivity for example. Children with OSA may experience learning and memory deficits, and OSA has been linked to lowered childhood IQ scores. Untreated OSA may prevent children from reaching their height potential.
Sources: en.wikipedia.org
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.
Reversed-phase chromatography with ultraviolet detection gives a purity percentage, while mass spectrometry confirms identity. Amino acid analysis checks the residue composition. Buyers typically request a certificate of analysis showing these measurements for the specific lot.
It is not authorised as a medicine in the United States or the European Union. Material is sold there as a research chemical or cosmetic ingredient. Some related short peptides are registered drugs in Russia, which is a distinct national situation rather than a general approval.
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.